Abstract
We aimed at comparing our long-term results after biliopancreatic diversion (BPD) with or without gastric preservation for morbid obesity. Between 1999 and 2009, we performed 540 BPD: 287 patients (group A) underwent BPD with distal gastric resection (BPD-AHS) and 253 (group B) underwent BPD associated with transitory vertical gastroplasty (TGR) with duodenal switch (DS). The results have been analyzed in terms of weight loss, improvement of comorbidities, and quality of life (Bariatric Analysis and Reporting Outcome System). The mean follow-up was 7.4 ± 2.9 years. One year after surgery, mean initial excess weight loss percentage was 69% for patients in group A (n = 287) and 65% for group B (n = 253); after 2–5 years, it was 74% for patients who underwent BPD-AHS (n = 130) and 75% for patients who underwent BPD-TGR-DS (n = 116); it was 71% and 74% for patients in group A (n = 157) and B (n = 137), respectively, followed up for >5 years (P = 0.27). Among the diabetic patients in both groups (191 patients), 64% discontinued the medication with insulin (P = 0.25), and 98% had stopped oral drugs within 1 year from surgery (P = 0.29). We did not observe deficiencies of vitamins and proteins. The overall incidence of incisional hernias was 38% (P = 0.35). We recorded 13 anastomotic ulcers (2.4%; P = 0.28). BPD represents, in spite of the side effects, an effective technique for treatment of morbid obesity and its associated diseases. Moreover, our results showed that patients who underwent BPD-TGR-DS had slightly better results in terms of postoperative metabolic complications and improvement in quality of life.
References
Stevens J, Cai J, Pamuk ER, et al. The effect of age on the association between body mass index and mortality. N Engl J Med. 1998;338:1–7.
Calle EE, Thun MJ, Petrelli MJ, et al. Body mass index and mortality in a prospective cohort of US adults. N Engl J Med. 1999;341:1097–105.
Scopinaro N, Marinari GM, Camerini GB, et al. Specific effects of biliopancreatic diversion on the major components of metabolic syndrome. Diab Care. 2005;28:2406–11.
O’Brien P, McPhail T, Chaston TB, et al. Systematic review of medium-term weight loss after bariatric operations. Obes Surg. 2006;16:1032–40.
Crea N, Pata G, Della Casa D, et al. Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis. Obes Surg. 2009;19:1084–8.
Crea N, Pata G, Di Betta E, Titi A, Mittempergher F. High incidence of appendix carcinoid tumors among candidates for bariatric surgery: diagnostic and therapeutic implications. Obes Surg. 2010 Feb 26. doi:10.1007/s11695-010-0112-4.
Marceau P, Biron S, Hould FS, et al. Duodenal switch: long-term results. Obes Surg. 2007;17:1421–30.
Jones KB. Bariatric surgery. Where do we go from here? Int Surg. 2004;89:51–7.
Scopinaro N, Giannetta E, Civalleri D, et al. Bilio-pancreatic by-pass for obesity: II. Initial experience in man. Br J Surg. 1979;66:613–20.
Scopinaro N, Giannetta F, Friedman D, et al. Evolution of biliopancreatic by-pass. Clin Nutr. 1986;5:137–46.
Scopinaro N, Giannetta F, Civalleri D, et al. Biliopancreatic diversion. In: Griffen WO, Printen KJ, editors. Surgical management of morbid obesity. New York: Marcel Dekker; 1987. p. 93–162.
Scopinaro N, Adami GF, Marinari GM, et al. Biliopancreatic diversion: two decades of experiences. In: Deitel M, editor. Update: surgery for the morbidly obese patient. Toronto: FD-Communications; 2000. p. 227–58.
Holst JJ. Glucagonlike peptide 1: A newly discovered gastrointestinal hormone. Gastroenterol. 1994;107:1848–55.
Ballinger A. Gastric inhibitory polypeptide links over-nutrition to obesity. Gut. 2003;52:319–20. Science@lert. http://www.gutjnl.com.
Rubino F, Marescaux J. Effect of duodenal–jejunal exclusion in a non-obese animal model of type 2 diabetes. Ann Surg. 2004;239:1–11.
Hess DS, Hess DW. Biliopancreatic diversion with a duodenal switch. Obes Surg. 1998;8:267–82.
Marceau P, Biron S, St. Georges R, et al. Biliopancreatic diversion with gastrectomy as surgical treatment of morbid obesity. Ann Surg. 1992;215:387–94.
Marceau P, Biron S, Lagacè M. Biliopancreatic diversion with distal gastrectomy 250 cm and 50 cm limbs: long term results. Obes Surg. 1995;5:302–7.
Marceau P, Hould FS, Simard S. Biliopancreatic diversion with duodenal switch. Orld J Surg. 1998;22:947–54.
Vassallo C, Negri L, Della Valle A, et al. Biliopancreatic diversion with transitory gastroplasty preserving duodenal bulb: 3 years experience. Obes Surg. 1997;7:30–3.
Cossu ML, Noya G, Tonolo GC, et al. Duodenal switch without gastric resection: results and observations after 6 years. Obes Surg. 2004;14:1354–9.
Anonymous. Gastrointestinal surgery for morbid obesity: National Institute of Health Consensus Development Conference Statement. Am J Clin Nutr, 1992; 55:615S–19S.
Mittempergher F, Di Betta E, Crea N, et al. Our experience in selecting patients for bariatric surgery. Ann Ital Chir. 2007;78:487–92.
Oria HE, Moorehead MK. Bariatric Analysis and Reporting Outcome System (BAROS). Obes Surg. 1998;8:487–99.
Moorehead MK, Ardelt-Gattinger E, Lechner H, et al. The validation of the Moorehead–Ardelt–Gattinger quality of life questionnaire II. Obes Surg. 2003;13:684–92.
Marinari GM, Murelli F, Camerini G, et al. A 15-year evaluation of biliopancreatic diversion according to the Bariatric Analysis Reporting Outcome System (BAROS). Obes Surg. 2004;14:325–8.
Frank A. Futility and avoidance. JAMA. 1995;269:2132–5.
Van Hee R. Biliopancreatic diversion in the surgical treatment of morbid obesity. World J Surg. 2004;28:435–44.
Mittempergher F, Di Betta E, Nascimbeni R, et al. Comparison between a bilio-pancreatic diversion with or without gastroresection after 2 years of follow-up in the treatment of the pathological obesity. Ann Ital Chir. 2008;79:241–6.
Di Betta E, Mittempergher F, Nascimbeni R, et al. Outcome of duodenal switch with a transitory vertical gastroplasty, in super-super-obese patients in an 8-year series. Obes Surg. 2008;18:182–6.
Scopinaro N, Papadia F, Camerini G, et al. A comparison of a personal series of biliopancreatic diversion and literature data on gastric bypass help to explain the mechanisms of resolution of type 2 diabetes by the two operations. Obes Surg. 2008;18:1035–8.
Larrad-Jimenez A, Diaz-Guerra CSC, de Cuadros Borrajo P, et al. Short-, mild- and long-term results of Larrad biliopancreatic diversion. Obes Surg. 2007;17:202–10.
Gueda ME, del Amo DA, Solanas JAG, et al. Results of biliopancreatic diversion after five years. Obes Surg. 2004;14:766–72.
Friedman D, Traverso G, Adami E, et al. Incisional hernias following biliopancreatic diversion. Obes Surg. 1996;6:304. Abst 21.
Sugerman HJ, Kellum Jr JM, Reines HD, et al. Greater risk of incision hernia with morbidly obese than steroid-dependent patients and low recurrence with prefascial polypropylene mesh. Am J Surg. 1996;171:80–4.
Scopinaro N, Marinari GM, Camerini G. Laparoscopic standard biliopancreatic diversion: technique and preliminary results. Obes Surg. 2002;12:241–4.
Fox R, Fox K. Vertical banded gastroplasty and distal gastric bypass as primari procedures: a comparison. Obes Surg. 1996;6:421–5.
Totté E, Hendrickx L, van Hee R. Biliopancreatic diversion for treatment of morbid obesity: experience in 180 consecutive cases. Obes Surg. 1999;9:161–5.
Buchwald H. A bariatric surgeon algorithm. Obes Surg. 2002;12:733–46. discussion 47–50.
Conflicts of Interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Crea, N., Pata, G., Di Betta, E. et al. Long-Term Results of Biliopancreatic Diversion with or Without Gastric Preservation for Morbid Obesity. OBES SURG 21, 139–145 (2011). https://doi.org/10.1007/s11695-010-0333-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11695-010-0333-6